Shares of Oncobiologics Inc (NASDAQ:ONS) have been given an average broker rating score of 3.00 (Hold) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating. Oncobiologics’ rating score has declined by 200% in the last three months as a result of various analysts’ ratings changes.
Brokerages have set a 12-month consensus price objective of $11.00 for the company, according to Zacks. Zacks has also assigned Oncobiologics an industry rank of 200 out of 265 based on the ratings given to related companies.
A number of equities research analysts have issued reports on ONS shares. ValuEngine upgraded Oncobiologics from a “strong sell” rating to a “sell” rating in a research note on Friday. Barclays cut Oncobiologics from an “overweight” rating to an “equal weight” rating in a research note on Monday.
Oncobiologics (ONS) remained flat at $$1.14 during mid-day trading on Friday. 35,955 shares of the company’s stock were exchanged, compared to its average volume of 64,715. The company has a quick ratio of 0.14, a current ratio of 0.14 and a debt-to-equity ratio of -0.40. Oncobiologics has a 52 week low of $0.78 and a 52 week high of $3.77.
In related news, CEO Pankaj Mohan sold 114,677 shares of Oncobiologics stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $1.17, for a total transaction of $134,172.09. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Lawrence A. Kenyon sold 26,165 shares of Oncobiologics stock in a transaction dated Friday, December 22nd. The shares were sold at an average price of $1.13, for a total transaction of $29,566.45. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 284,508 shares of company stock worth $328,317. Company insiders own 33.50% of the company’s stock.
An institutional investor recently raised its position in Oncobiologics stock. Sabby Management LLC increased its position in shares of Oncobiologics Inc (NASDAQ:ONS) by 5.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,365,763 shares of the company’s stock after acquiring an additional 127,293 shares during the period. Sabby Management LLC owned approximately 9.59% of Oncobiologics worth $2,371,000 at the end of the most recent quarter. Institutional investors and hedge funds own 17.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/02/zacks-analysts-set-11-00-target-price-for-oncobiologics-inc-ons.html.
Oncobiologics Company Profile
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
Get a free copy of the Zacks research report on Oncobiologics (ONS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.